I N T R O D U C T I O N
For peritoneal dialysis (PD) patients, the peritoneal membrane is injured by bioincompatible dialysis solutions, uremia and peritonitis [1] . Loss of the mesothelial cell monolayer, submesothelial thickening and angiogenesis are associated with functional changes such as increased solute transport [2] . Increased solute transport has been associated with the failure of ultrafiltration [3] and increased risk of mortality [4] . Thickening of the submesothelial zone and the angiogenic response have been associated with accumulation of submesothelial myofibroblasts [5] . The origin of these myofibroblasts is controversial. We have shown that a portion of these cells derive from the mesothelium in a process of epithelial mesenchymal transition (EMT) [6] . Others have shown that the majority of submesothelial myofibroblasts derive from existing interstitial fibroblasts [7] .
Metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases involved in fibrotic and remodeling processes. MMP2 and MMP9 are gelatinases that degrade type IV collagen, an important structural component of the basement membrane [8] . Previous studies have demonstrated a role for MMP2 and MMP9 in cellular invasion as a component of EMT [9] . We have previously demonstrated that platelet-derived growth factor B (PDGF-B) induces a noninvasive EMT phenotype where the mesothelial cells transition but do not invade into the submesothelium [10] . This is in contrast to transforming growth factor b (TGF-b)-induced peritoneal fibrosis, which was associated with the appearance of transitioned epithelium in the submesothelial tissue [6] . TGF-b overexpression is associated with increased MMP2 and MMP9 expression [6] , whereas PDGF-Binduced fibrosis did not increase gelatinase expression [10] . Therefore, gelatinases may be required to degrade the basement membrane to facilitate invasion of transitioned cells into the submesothelial zone.
MMP2 and MMP9 are angiogenic and are associated with increased activity of vascular endothelial growth factor (VEGF) [11] . They are also involved in cleavage of cell surface proteins and elaboration of growth factors from matrix stores [12] . Ecadherin is an epithelial cell adhesion protein found on peritoneal mesothelial cells, and loss of E-cadherin is essential in EMT [13] . MMP9 has been shown to cleave the extracellular domain of E-cadherin, resulting in an 80-kDa E-cadherin fragment [14] . The intracellular domain of E-cadherin is associated with b-catenin, which connects to the cell's actin cytoskeleton. Ecadherin cleavage leads to increased concentration of cytosolic b-catenin, which can then act as a transcription factor that regulates a variety of genes involved in cell growth and differentiation, including MMPs, c-myc and VEGF [15] . The goal of this study was to identify the role of MMP9 in peritoneal membrane injury. Specifically, we analyzed mesothelial cells derived from peritoneal effluent from patients on PD to evaluate MMP9 expression and markers of peritoneal membrane function. Furthermore, we examined the effect of MMP9 on peritoneal angiogenesis, fibrosis and cellular invasion. We hypothesized that MMP9 induces peritoneal angiogenesis by cleavage of Ecadherin and signaling through b-catenin to upregulate VEGF.
M A T E R I A L S A N D M E T H O D S
Human mesothelial cell culture A 2 L sample of overnight dwell of peritoneal fluid effluent was taken from 33 stable PD patients with no peritonitis within 3 months of enrollment in the study. PD effluent was centrifuged and mesothelial cells were resuspended in F12 media and cultured. At the same clinic visit, positron emission tomography was carried out using a 4-h dwell of 4.25% glucose solution as previously described [16] . Solute transport data, including dialysate:plasma creatinine ratio (D/P creatinine) and a 4 h:initial PD fluid glucose ratio (D/D 0 glucose), were obtained. Local ethics board approval was obtained and patients provided informed consent.
Gene expression analysis
After two passages, human mesothelial cells were suspended in Trizol reagent and RNA was isolated. mRNA was evaluated using both nCounter (nanoString Technologies, Seattle, WA, USA) and quantitative real-time PCR. nCounter has been previously described by Kulkarni et al. [17] . Briefly, customized probes for a panel of 31 genes associated with matrix MMP, cell differentiation and angiogenesis, along with 4 housekeeping genes, were created (Supplementary data, Table S1 ). We initially compared a subset of seven MMP-associated genes with D/P creatinine. We selected these genes based on a literature search of MMPs associated with fibrosis and included representation of the major MMP families [18] . We then compared MMP9 gene expression with the entire 31-gene panel. Probes were hybridized to 100 ng of total RNA. Data were collected using the nCounter Digital Analyzer by counting individual barcodes. Positive and negative controls were included. mRNA counts were normalized using the geometric mean of the four housekeeping genes.
For quantitative real-time PCR, 1 mg of RNA obtained was reverse transcribed, and gene expression for MMP9 was determined using the ABI Prism 7500 Sequence Detector (Applied Biosystems, Life Technologies, Burlington, ON, Canada). Samples were run in duplicate and normalized to 18 s.
Recombinant adenovirus
We used three different adenoviruses in these experiments: AdTGFB, AdMMP9 and AdDL. AdDL is a null adenovirus used as viral control. AdTGFB expresses constitutively active TGF-b1 [19] . AdMMP9 expresses human MMP9 [20] . Amplification and purification of adenoviruses were completed by Cesium chloride gradient centrifugation and plaque-titered on 293 cells as previously described [21] .
Animal experiments
All animal studies were performed according to the Canadian Council on Animal Care guidelines with local ethics board approval. C57BL/6 mice received an injection of 3 Â 10 8 plaque-forming units (pfu) of AdMMP9 (n ¼ 7) and controls were treated with AdDL (n ¼ 8). All adenoviruses were diluted in 100 lL of saline and administered by intraperitoneal (i.p.) injection. One hour prior to euthanization, the animals received an i.p. injection of 3 mL of 4.25% glucose dialysis solution (Dianeal, Baxter Healthcare, Mississauga, ON, Canada). Animals were euthanized 10 days after adenovirus injection.
An additional group of mice were treated with AdMMP9 (n ¼ 10). At Day 4, animals were administered daily i.p. injections (5 mg/kg) of ICG-001 (Millipore, Etobicoke, ON, Canada) for 5 days (n ¼ 5). All animals received a 3-mL i.p. injection of 4.25% Dianeal (Baxter Healthcare) 1 h before euthanization. Animals were euthanized 10 days after initial AdMMP9 injection.
Both MMP2 À/À mice (Baylor College of Medicine, Houston, TX, USA) [22] and MMP9 À/À mice (Jackson Laboratories, Bar Harbor, ME, USA) [23] were on a C57BL/6 background. C57BL/6 (n ¼ 13), MMP2 À/À (n ¼ 13) and MMP9 À/À (n ¼ 13) mice were administered 0.8 Â 10 8 pfu of AdTGFB diluted to 100 mL of saline via the i.p. route. AdTGFB induced fibrosis and EMT in the peritoneum. Animals were also treated with control adenovirus (n ¼ 13). As above, all animals received a 3-mL i.p. injection of 4.25% Dianeal (Baxter Healthcare) 1 h before euthanization, which was carried out 10 days after adenovirus infection.
For all experiments, the peritoneum was opened and the entire peritoneal fluid content was collected by pipette. The anterior abdominal wall was removed and stored in 4% neutral buffered formalin. The omentum was taken and frozen in liquid nitrogen for protein analysis.
Histology
Peritoneal membrane samples from the anterior abdominal wall were initially fixed in 10% formalin for 48 h and paraffin embedded. Fixed sections were stained with Masson's trichrome. Immunostaining for blood vessels was performed using von Willebrand factor antibody/factor VIII (1:150) (Dako, Burlington, ON, Canada). Northern Eclipse software (Empix Imaging, Mississauga, ON, Canada) was used to analyze the blood vessel density and submesothelial thickness. Photomicrographs (5-10 per section) were taken and vascular density was calculated in rectangles 100, 200 and 500 mm deep from the mesothelial cell layer. Submesothelial thickness was calculated by measuring the average distance from the superficial mesothelial cell layer to the muscle. Immunostaining of the laminin basement membrane was performed using a polyclonal antibody against laminin (1:50) (Millipore). For b-catenin, we used a monoclonal antibody that is specific for the nonphosphorylated or active b-catenin (Millipore) [24] . For quantification of b-catenin expression, photomicrographs (5-10 per section) were taken and positive-stained cells were counted.
Immunofluorescence was completed using a monoclonal mouse anti-human a smooth muscle action (a-SMA) antibody (1:50) (Dako, Burlington, ON, Canada) with a Texas Red goat anti-mouse secondary antibody (1:100) (Molecular Probes, Life Technologies) followed by a FITC-labeled monoclonal mouse antibody against pan-cytokeratin (1:50) (Sigma-Aldrich, Oakville, ON, Canada). To control for nonspecific staining, sections were exposed to the secondary antibody without the primary a-SMA antibody. To confirm dual labeling, we also stained representative sections directly with a fluorescently labeled a-SMA antibody (Cy3, Sigma-Aldrich) (Supplementary data, Figure S1 ). ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used to analyze and quantify duallabeled cells in the mesothelial and submesothelial layers. Duallabeled cells co-expressing a-SMA and pan-cytokeratin were identified in the mesothelial cell layer and in the submesothelial cell layer from five high-power fields from each section, and this was using a blinded approach. Dual-labeled cells in the mesothelial layer were categorized as noninvading cells and duallabeled cells in the submesothelium were considered invading cells.
Mesothelial cells were grown on 22 Â 22-mm glass cover slips in a 35-mm dish for immunofluorescence. The cells were fixed and permeabilized with 100% methanol and stained with a FITC-labeled monoclonal mouse antibody against pancytokeratin (1:50) (Sigma-Aldrich).
Protein analysis
Protein was extracted from frozen omental peritoneal tissue. Samples were electrophoresed on a 10% SDS-PAGE gel and probed for E-cadherin (BD Biosciences, Mississauga, ON, Canada), E-cadherin fragment (Santa Cruz Biotechnology, Dallas, TX, USA), MMP9 (Abcam, Toronto, ON, Canada), MMP2 (Santa Cruz) and VEGF (Millipore). Alpha tubulin (Abcam) and b-actin (Sigma-Aldrich) were used as loading controls. For the peritoneal effluent, a nonspecific band on Coomassie blue-stained blots was used as the loading control.
Gelatin zymography was performed on an 8% SDS-PAGE with 0.1% gelatin (Sigma). Gels were soaked in 2.5% Triton X-100 for 30 min to remove SDS. They were then incubated in activation buffer (50 mM Tris-HCl; pH 8, 10 mM CaCl 2 , 5 lM ZnSO 4 and 150 mM NaCl) for 12 h at 37 C. Following incubation, activity was observed using Coomassie blue and quantified (ImageJ).
Peritoneal effluent concentration of VEGF was measured using a standard ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Statistical analysis
Data are presented as mean 6 SD. Correlations were assessed by Spearman's coefficient. A Bonferroni correction was used for multiple comparisons. For comparison between groups, the Kolmogorov-Smirnov test was used to confirm normally distributed data. For normally distributed data, a t-test was used to compare between two groups and ANOVA with post hoc Tukey's test was used for multiple groups. A MannWhitney test was used for nonnormally distributed data.
R E S U L T S

MMP9 is correlated with peritoneal membrane solute transport
We studied a total of 33 stable PD patients. The average age of the patients was 62 (613) years. Forty-five percent had diabetes. The average PD duration was 1.4 (61.3) years. Using nanoString gene expression analysis, we measured seven MMP genes in exvivo-derived mesothelial cell culture and examined the association with the patients' peritoneal membrane solute transport properties ( Figure 1A ). Of our seven-gene MMP panel, MMP9 was found to be most strongly associated with D/ P creatinine (r ¼ 0.746, P < 0.001), but MMP7 was also significantly associated with solute transport ( Figure 1A ). Gene expression of MMP14 was correlated with solute transport in univariate analysis but is no longer significant after the Bonferroni correction for multiple comparisons ( Figure 1A) . Notably, MMP2 gene expression did not correlate with solute transport ( Figure 1A) . We confirmed the association between ex vivo mesothelial cell gene expression of MMP9 and solute transport using quantitative PCR. MMP9 gene expression correlated with D/P creatinine ( Figure 1B ) and inversely with D/ D0 glucose ( Figure 1C) . We compared MMP9 gene expression measured by nanoString with quantitative real-time PCR and found a very close correlation (r ¼ 0.804, P < 0.001) ( Figure 1D ). MMP9 gene expression in ex vivo mesothelial cells was also higher in patients with diabetes than those without (1.0 versus 0.6, P ¼ 0.01; data not shown).
The peritoneal effluent initially contained $5% mesothelial cells. After two passages in cell culture, the cells were virtually Figure S2 ).
MMP9 overexpression leads to submesothelial thickening and angiogenesis
Because of this association between peritoneal membrane solute transport and mesothelial MMP9 gene expression, we used an adenovirus to overexpress MMP9 in the peritoneal membrane of mice (Figure 2A and B) . The control adenovirus (AdDL) did not alter peritoneal membrane structure (Figure 2A ). AdMMP9 led to submesothelial thickening, fibrosis and angiogenesis. The mesothelial cells appear to be reactive, with increased cell number and hypertrophy. These histologic changes were quantified from factor VIII-stained sections ( Figure 2C and D, quantified in E and F). Submesothelial thickness increased by 2-fold (P ¼ 0.004) and angiogenesis increased by 3-fold (P < 0.001) in response to AdMMP9. AdMMP9 induced a significant increase in VEGF protein concentration in the peritoneal effluent taken from these mice at the time of euthanasia ( Figure 2G ). We used zymography to confirm MMP9 expression after infection with AdMMP9 ( Figure 2H and I) and noted that AdMMP9 also significantly upregulated MMP2 expression ( Figure 2J ).
MMP9 leads to mesothelial cell transition
We used immunofluorescence labeling of epithelial and mesenchymal markers to investigate the peritoneum for evidence of EMT and cellular invasion ( Figure 3A-D) . Control adenovirustreated animals showed cytokeratin-positive mesothelium with no evidence of dual labeling with (a-SMA) ( Figure 3A-C) . Animals treated with AdMMP9 demonstrated an increase in dual-labeled mesothelial cells suggestive of EMT (Figure 3D-F) . There was no evidence of accumulation of submesothelial duallabeled cells, suggesting a lack of mesothelial cell migration after transition ( Figure 3H) .
Decreased E-cadherin expression is a hallmark of mesothelial cell transition, and we found that MMP9 overexpression led to a significant decrease in E-cadherin expression in peritoneal tissue ( Figure 3I and J).
Angiogenesis is inhibited in MMP9
À/À mice
Our results from human mesothelial cells suggested that MMP2 and MMP9 may have distinct actions with respect to peritoneal membrane injury (Figure 1) . We induced peritoneal fibrosis in mice using an adenovirus expressing active TGF-b1 in MMP2
À/À and MMP9 À/À mice ( Figure 4A-F) . We confirmed that the MMP2 À/À and MMP9 À/À mice were deficient Figure 4H ) and increased cell numbers. In addition, AdTGFB induced an increase in blood vessel density in C57Bl/6 and MMP2 À/À mouse peritoneum ( Figure 4I ). However, this angiogenic response to TGF-b was not seen in the MMP9 À/À mice. ELISA analysis of peritoneal effluent revealed significantly increased levels of VEGF in C57Bl/6 and MMP2 À/À mice treated with AdTGFB, whereas MMP9 À/À mice did not display a similar increase in VEGF ( Figure 4J ).
TGF-b-induced mesothelial cell transition is reduced in MMP9
We evaluated the effect of MMP9 deficiency on mesothelial cell transition and invasion using dual immunofluorescence with cytokeratin and a-SMA to identify transitioned cells. TGFb1 induced mesothelial cell transition and invasion in C57Bl/6 mice ( Figure 5A-C, quantified in G) . MMP9
À/À mice treated with TGF-b1 exhibited significantly lower levels of transitioned cells with no evidence of cellular invasion ( Figure 5D-F) . Laminin staining suggested that MMP9 À/À mice were protected against TGF-b-induced basement membrane degradation (Supplementary data, Figure S3 ).
MMP9 cleaves E-cadherin
As noted previously, AdMMP9-treated peritoneal tissue demonstrated a decrease in E-cadherin protein ( Figure 3I and J), suggesting that MMP9 is involved in downregulation of Ecadherin. We determined whether MMP9 was involved in Ecadherin cleavage from the cell surface by measuring the amount of E-cadherin fragment (80 kDa) in the peritoneal effluent from mice treated with AdMMP9. Western blot analysis revealed a 3-fold (P ¼ 0.007) increase in fragmented E-cadherin in response to MMP9 ( Figure 6A and B) . We also evaluated levels of E-cadherin fragment in the peritoneal effluent from TGFb-induced fibrosis in MMP2-or MMP9-deficient mice. Western blot analysis showed a significant increase in fragmented E-cadherin in the peritoneal effluent in C57Bl/6 and MMP2 À/À animals treated with AdTGFB1 ( Figure 6C and D).
MMP9
À/À mice treated with AdTGFB1 exhibited significantly lower levels (1.5-fold, P ¼ 0.05) of fragmented E-cadherin in the peritoneal effluent compared with C57Bl/6 mice treated with AdTGFB ( Figure 6D ). 
MMP9 signals through b-catenin
Our findings indicate that MMP9 is essential in cleaving Ecadherin and is associated with an upregulation of VEGF and angiogenesis in peritoneal membrane injury. We hypothesize that MMP9-induced E-cadherin cleavage may lead to dissociation of the E-cadherin/b-catenin complex and facilitate b-catenin translocation to the nucleus. To support this, we found an increase in active b-catenin seen in the peritoneal membrane in animals treated with AdMMP9 ( Figure 6E , quantified in G). This was not observed in the control adenovirus-treated mice ( Figure 6F) . Consistent with our in vivo experiments, MMP9 expression in the patient-derived mesothelial cell culture was correlated with transcription factors associated with cellular transition (SNAIL1, TWIST) and genes associated with angiogenesis (VEGF, angiopoietin 2) ( Figure 6H ). We also observed a correlation between MMP9 gene expression and other genes involved in the WNT signaling pathway, including WNT1, WNT5A and the WNT receptors FZD3 and LRP6. MMP7, VEGF and c-myc are known to be regulated by b-catenin signaling and were all significantly associated with MMP9 gene expression.
In order to directly assess the role of b-catenin in MMP9-induced angiogenesis, we blocked b-catenin with a specific T-cell factor/lymphoid enhancer factor (TCF/LEF) inhibitor, ICG-001 [25] , in mice after infection with AdMMP9. Analysis of blood vessel density in the mouse peritoneum after adenovirus gene transfer confirmed that MMP9 induces an increase in blood vessel density in the peritoneum ( Figure 7A and B) . ICG-001 inhibited this angiogenic response ( Figure 7C , quantified in E). ICG-001 did not induce significant changes in submesothelial thickness ( Figure 7D ). Animals treated with ICG-001 demonstrated a 4-fold (P ¼ 0.023) reduction in VEGF protein measured in the peritoneal tissue by western blot (Figure 7F and G).
D I S C U S S I O N
The peritoneal membrane is a lifeline for patients with endstage kidney disease on PD therapy. Injury to the peritoneum results in both structural and functional changes. Blood vessel formation is of critical importance since it is associated with high transport status [26] and a decline in peritoneal membrane function. In our study, we measured the gene expression of MMPs in mesothelial cells derived from overnight effluent from stable PD patients. Ex vivo mesothelial cell MMP9 mRNA expression was significantly correlated with peritoneal Several recent studies have evaluated biomarkers of early peritoneal membrane injury in order to optimize renal replacement therapy [27, 28] . Our observations suggest that ex vivo mesothelial cell MMP9 mRNA expression may be a useful biomarker in peritoneal membrane injury in PD patients, but this result needs to be confirmed in a larger cohort of stable PD patients with longitudinal follow-up.
Recent studies by Barreto et al. [28] , Cho et al. [29] and Hirahara et al. [30] demonstrated that MMP2 measured in the peritoneal effluent correlated with peritoneal membrane solute in large population studies. In the study by Barreto et al. [28] , MMP2 was measured in 86 stable PD patients and the intraperitoneal production of MMP2 was estimated. In larger studies by Cho et al. [29] and Hirahara et al. [30] , total MMP2 in the peritoneal effluent was measured by ELISA. In our study, we evaluated both MMP2 and MMP9 gene expression in mesothelial cells derived from the peritoneal effluent. This ensured that the MMP expression reflects local intraperitoneal production.
The close correlation between mesothelial cell MMP9 expression and peritoneal solute transport suggests that mesothelial-derived MMP9 may be a useful biomarker and may be directly involved in the pathology of peritoneal membrane injury.
Our results are discordant with the other three studies that have identified MMP2 as a potential biomarker for peritoneal membrane injury [27, 28] . The MMP9 enzyme is found at a low concentration in the peritoneal effluent, whereas MMP2 is found at a much higher concentration and is thus more easily measured [27, 28] . Furthermore, our results suggest that MMP2 is induced by MMP9 in the peritoneal tissues ( Figure 2J ), suggesting that locally active MMP9 may induce MMP2, which can then be measured in the PD effluent. This suggests that mesothelial-derived MMP9 may be an earlier indicator of peritoneal membrane injury. Hirahara et al. [31] have also shown that in an animal model of peritoneal fibrosis, the majority of MMP2 detected in the peritoneal effluent is not active, but in situ film zymography shows extensive gelatinase activation within the injured peritoneal membrane, which suggests local activation of gelatinases within the peritoneal tissue. We have identified a novel mechanism for MMP9-mediated peritoneal angiogenesis. Specifically, our results suggest that MMP9 leads to E-cadherin cleavage and activation of b-catenin signaling. Cleavage of a 50-84-kDa-sized N-terminal fragment of E-cadherin is an essential step in epithelial cell transition and has been studied extensively in the setting of epithelial malignancies [32] . MMP9 has been reported to cleave an 80-kDa Ecadherin fragment in ovarian carcinoma cells [33] . Our results agree with these studies. We found that AdMMP9-treated mice had increased amounts of E-cadherin fragment in the peritoneal effluent ( Figure 6A and B) . Similarly, we found that wild-type and MMP2
À/À mice treated with AdTGFB1 had high levels of E-cadherin fragment in the peritoneal effluent; this was greatly reduced in MMP9 À/À mice exposed to TGF-b1 ( Figure 6C and D) .
Several studies have identified that cleavage of E-cadherin can lead to b-catenin signaling [32, [34] [35] [36] . b-catenin is sequestered by E-cadherin at the cell membrane as part of the adherens junction. With E-cadherin cleavage, b-catenin is released into the cytosol. Cytosolic b-catenin is rapidly degraded, and activation of the canonical WNT pathway is required to inhibit b-catenin ubiquitination [37] . Therefore, we hypothesize that in MMP9-induced peritoneal injury, there is likely activation of WNT signaling that facilitates b-catenin-mediated gene expression. In support of this, we found a correlation between MMP9 gene expression in patient-derived mesothelial cells and gene expression of other WNT signaling molecules such as WNT1 and the receptors FZD3 and LRP5. There was simultaneous activation of several b-catenin-regulated genes, including MMP7, MMP14, VEGF and c-myc ( Figure 6H ).
Previous studies have identified the role of MMP9 in angiogenesis in the setting of tumor cell metastasis [38] , fibrosis [39] and ischemia [40] . MMPs have been hypothesized to be involved in degrading the basement membrane of blood vessels to allow endothelial cells the ability to migrate and form new blood vessels [41] . MMPs may also contribute to angiogenesis through the release of ECM-bound proangiogenic factors [40] , including VEGF. Our results support an angiogenic function of MMP9 as we observed increases in both VEGF and angiogenesis when MMP9 was overexpressed in the mouse peritoneum. The angiogenic response to peritoneal overexpression of TGF-b was attenuated in MMP9 À/À but not in MMP2 À/À mice. We did not assess the association between MMPs and uremia due to the lack of uremia in this model. Furthermore, our results suggest a novel mechanism by which MMP9 induces VEGF to promote blood vessel growth. We propose that MMP9 induces b-catenin signaling, which increases expression of VEGF. We observed nuclear localization of active b-catenin in peritoneal tissues after overexpression of AdMMP9 (Figure 6F , quantified in G). Furthermore, we used the b-catenin signaling inhibitor ICG-001 in the peritoneum of Previous studies have demonstrated a role for SMAD signaling in TGF-b-induced VEGF expression [42] . Our data suggest both SMAD and MMP9 may be involved in regulating VEGF expression. In fact, these pathways have been linked by observations that SMAD and b-catenin cooperate in nuclear signaling [43] .
MMPs have been involved in remodeling of the ECM, but their role in fibrosis has not been fully elucidated. Several studies describe MMPs as contributing to the progression of fibrosis [44, 45] ; however, recent evidence demonstrates that MMPs may have a more protective effect [46] . This discordance may be attributed to differences in function of diverse types of MMPs, as collagenases degrade collagen and may be more protective and gelatinases degrade basement membrane and may be more injurious.
The role of EMT in fibrosis has become increasingly controversial. Studies in both the kidney [47] and the peritoneum [7] suggest that transition of mesothelial cells does not contribute significantly to the accumulation of submesothelial myofibroblasts characteristic of fibrosis. Despite these observations, the epithelium likely has a key role in driving peritoneal fibrosis indirectly, and this process may require epithelial cellular transition without migration into the submesothelium [48] . Aroeira et al. [5] previously found that the cells grown from the peritoneum of PD patients take on different morphologies, from epithelial-like to fibroblastlike. They demonstrated an association between cell morphology and peritoneal membrane transport that we were unable to replicate in our patients (Supplementary data, Figure S4 ).
Abnormal expression of MMP9 has been implicated in induction of EMT [44] and fibrosis [49] . Tan et al. [50] found that MMP9 causes EMT of renal tubular epithelial cells in vitro. Our observations support these findings. We found infection with AdMMP9-induced colocalization of epithelial and mesenchymal markers in cells, suggesting an EMT process (Figure 3 ). We also found that the TGFb-induced EMT response was attenuated in MMP9 À/À mice ( Figure 5 ). There are extensive data from cancer research to suggest that MMP2 [51] and MMP9 [52] are directly involved in cellular invasion after EMT. It is clear that MMP2 and MMP9 can effectively degrade basement membrane proteins in an in vitro assay using material such as matrigel [32, 53] . However, cross-linked mature basement membrane may not be susceptible to gelatinase activity [54] . Our study demonstrated potential degradation of basement membrane in response to AdMMP9 and AdTGFB. Laminin-stained sections from these mice demonstrated areas of decreased or absent basement membrane, whereas the control adenovirus-treated mice demonstrated a continuous basement membrane structure (Supplementary data, Figure S2 ). Transitioned mesothelium does not constitute a large component of submesothelial myofibroblasts after peritoneal membrane injury [7] , and our data do not support a role for MMP9 in cellular invasion ( Figure 3H) .
Therefore, in the setting of peritoneal membrane injury, MMP9 appears to have a role in the induction of EMT but does not facilitate cellular invasion. MMP9 also has a role in peritoneal membrane angiogenesis, and we have identified a novel b-catenin-mediated pathway for this response. This expands potential therapeutic options for preservation of the peritoneal membrane in PD patients by targeting the MMP or WNT pathways. Furthermore, mesothelial cell MMP9 mRNA may be a potential biomarker for peritoneal membrane injury and could eventually be used to guide PD therapy.
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